Enanta Pharmaceuticals Inc

NASDAQ:ENTA   3:59:55 PM EDT
41.33
-0.67 (-1.60%)
Products

Enanta Pharmaceuticals Presents New Data For EDP-721

Published: 06/23/2021 06:10 GMT
Enanta Pharmaceuticals Inc (ENTA) - Enanta Pharmaceuticals Presents New Data for Edp-721, an Oral Hepatitis B Virus Rna Destabilizer.
Enanta- Data Demonstrate Potent, Selective and Pangenotypic Inhibition of Hbv Surface Antigen (hbsag), With Up to a 3-log Drop in Aav-hbv Mouse Model.
Enanta - Data Presented Support Continued Development of Edp-721 for Use in an All-oral Regimen to Provide a Functional Cure for Hbv.
Enanta-expects to Initiate Phase 1 Single Ascending Dose,multiple Ascending Dose Study to Evaluate Safety of Edp-721 in Healthy Volunteers in Mid-2021.